Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
REVB

REVB - Revere Bank Stock Price, Fair Value and News

$2.09+1.57 (+301.92%)
Market Closed

Price Targets

REVB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

REVB Price Action

Last 7 days

148.8%

Last 30 days

137.5%

Last 90 days

67.2%

Trailing 12 Months

-83.6%

REVB RSI Chart

REVB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

REVB Valuation

Market Cap

12.4M

Price/Earnings (Trailing)

-1.52

Price/Sales (Trailing)

859.07

Price/Free Cashflow

-1.23

REVB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

REVB Fundamentals

REVB Revenue

Revenue (TTM)

6.9K

REVB Earnings

Earnings (TTM)

-8.1M

Earnings Growth (Yr)

14.92%

Earnings Growth (Qtr)

21.98%

REVB Profitability

Return on Equity

-73.88%

Return on Assets

-63.22%

Free Cashflow Yield

-81.17%

REVB Investor Care

Shares Dilution (1Y)

6524.61%

Diluted EPS (TTM)

101.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20212.9K4.2K5.6K6.9K
20200001.6K
Get all data in R, Python etc through our Historical Stock Data APIs

About Revere Bank

REVB
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, urinary tract infection, sepsis, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
 CEO
 WEBSITErevbiosciences.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES6

Revere Bank Frequently Asked Questions

REVB is the stock ticker symbol of Revere Bank. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Revere Bank is 12.38 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check REVB's fair value in chart for subscribers.

The fair value guage provides a quick view whether REVB is over valued or under valued. Whether Revere Bank is cheap or expensive depends on the assumptions which impact Revere Bank's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for REVB.

As of Wed Jan 28 2026, REVB's PE ratio (Price to Earnings) is -1.52 and Price to Sales (PS) ratio is 859.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. REVB PE ratio will change depending on the future growth rate expectations of investors.